Results 1 to 10 of about 4,766 (189)

Stimulating Effect of Elvitegravir on Suicidal Erythrocyte Death [PDF]

Cellular Physiology and Biochemistry, 2016
Background/Aims: The antiviral drug Elvitegravir is used for the treatment of Human Immunodeficiency Virus (HIV) infections. The present study explored whether the drug is able to trigger eryptosis, the suicidal death of erythrocytes.
Rosi Bissinger, Abdulla Al Mamun Bhuyan, Elena Signoretto, Florian Lang   +3 more
doaj   +6 more sources

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS

HIV/AIDS: Research and Palliative Care, 2014
Krishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency
Pandey KK
doaj   +6 more sources

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system. [PDF]

HIV Med
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Zhang L, Chen L, Tang J, Liu X, Zheng L, Wang F, Huang X, Cao W, Li T.   +8 more
europepmc   +2 more sources

HIV-1 Resistance to Dolutegravir in Benin: The Need to Improve and Strengthen Therapeutic Patient Education Strategies to Achieve the Third Objective 95 of UNAIDS 95-95-95 Target. [PDF]

Case Rep Infect Dis
Benin has adopted the WHO 2019 recommendations by integrating dolutegravir into the first‐ and second‐line treatment regimen with regular monitoring of the emergence of resistance. The standard of care document has been updated, and healthcare staff have been trained on dosage, drug interactions, and the management of adverse effects.
Tchiakpe E, Diop-Ndiaye H, Osawe S, Toure-Kane C, Yessoufou A.   +4 more
europepmc   +2 more sources

Curcumin-enhanced elvitegravir therapy mitigates neuroinflammation and cognitive deficits in EcoHIV mice [PDF]

Experimental Biology and Medicine
HIV-associated neurocognitive disorders (HAND) persist in up to 50% of people living with HIV (PLWH) despite effective antiretroviral therapy (ART), driven by chronic neuroinflammation, oxidative stress, and neuronal damage.
Sandip Godse, Lina Zhou, Namita Sinha, Mohd Salman, Tauheed Ishrat, Santosh Kumar   +5 more
doaj   +2 more sources

Presentations Due to Priapism in an Urban Hospital in Switzerland. [PDF]

Emerg Med Int
Objective Priapism, a persisting erection not associated with sexual stimulation, can be ischaemic, with the risk of permanent erectile dysfunction, or nonischaemic. Drugs—e.g., injection therapies for erectile dysfunction, as well as neuroleptics, antidepressants and various other medicines—can also cause priapism.
Uhl JD, Koneval L, Schneidewind L, Haschke M, Exadaktylos A, Liakoni E.   +5 more
europepmc   +2 more sources

Synergistic antifungal activity of antiretrovirals with amphotericin B against Aspergillus species. [PDF]

PLoS ONE
Aspergillosis is a life-threatening fungal infection that primarily affects the lungs of immunocompromised individuals, including those living with human immunodeficiency virus (HIV), and is associated with mortality rates exceeding 50%. The infection is
Ammar A Khan, Ehab A Salama, Mohamed N Seleem   +2 more
doaj   +2 more sources

Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg [PDF]

Journal of the International AIDS Society
Introduction Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was efficacious and well tolerated in children/adolescents with HIV (aged ≥6 years, weighing ≥25 kg) in a Phase 2/3 study.
Eva Natukunda, Aditya H. Gaur, Pope Kosalaraksa, Elizabeth Hellström, Renate Strehlau, Afaaf Liberty, Stephanie Cox, Rory Leisegang, Ramesh Palaparthy, Susanne Crowe, Vinicius Vieira, Kathryn Kersey, Natella Rakhmanina   +12 more
doaj   +2 more sources

HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases

Journal of the International Association of Providers of AIDS Care, 2019
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1 treatment and has rare emergence of drug resistance.
S Lena Kang-Birken
exaly   +2 more sources

Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis. [PDF]

HIV Med
Abstract Objective This study evaluated rates of treatment‐emergent resistance‐associated mutations (TE‐RAMs) and discontinuation due to adverse events (DC‐AEs) across integrase strand transfer inhibitor (INSTI)‐based single‐tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV.
Rashid I, Unger NR, Willis C, Dhippayom T, Ramgopal M, Sherman EM, Yared N, Safran R, Swiatlo E, Weinberg AR, Navadeh S, Schmutz HW, Chaiyakunapruk N.   +12 more
europepmc   +2 more sources